Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 17/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682944 | 0.82 | TYMP (0.65) | TYMPALOX15PNP | |
| SCHEMBL1690698 | 0.81 | TYMP (0.51) | TYMPALOX15MAPT | |
| SCHEMBL10655644 | 0.72 | TYMP (0.47) | TYMPPNP | |
| SCHEMBL6574092 | 0.67 | TYMP (0.50) | TYMPPNP | |
| SCHEMBL6572727 | 0.67 | TYMP (0.52) | TYMPPNP | |
| SCHEMBL11002379 | 0.67 | TYMP (0.50) | TYMPMAPTPNP | |
| SCHEMBL9006994 | 0.67 | TYMP (0.63) | TYMPALOX15MAPT | |
| SCHEMBL1682985 | 0.67 | TYMP (0.63) | TYMPALOX15MAPT | |
| SCHEMBL9006882 | 0.67 | ALOX15 (0.67) | TYMPALOX15MAPT | |
| SCHEMBL6574229 | 0.65 | TYMP (0.72) | TYMPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440675-B2 | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| EP-2036903-B1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-8148381-B2 | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20120010165-A1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20090286755-A1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036903-A1 | POTENTIATOR OF RADIATION THERAPY | Taiho Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010165-A1 | POTENTIATOR OF RADIATION THERAPY | MGMT, RAD1, UNG | TYMP 79/4885ALOX15 3309/4885MAPT 4758/4885 |
| US-20090286755-A1 | POTENTIATOR OF RADIATION THERAPY | MGMT, RAD1, UNG | TYMP 79/4885ALOX15 3309/4885MAPT 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.